Liposomal Bupivacaine in Total Knee Arthroplasty
Knee Osteoarthritis, Anesthesia, Local
About this trial
This is an interventional treatment trial for Knee Osteoarthritis focused on measuring liposomal bupivacaine, total knee arthroplasty
Eligibility Criteria
Inclusion Criteria:
- primary knee osteoarthritis undergoing unilateral knee replacement
Exclusion Criteria:
- hypersensitivity and/or allergies to local anesthetics or previous knee surgery
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Adductor block protocol
peri-articular injection
An ultrasound-guided injection of Subsartorial saphenous nerve using Exparel 266 mg (20 cc vial) via a 21-gauge 4-inch Stimuplex A needle (B. Braun Medical Inc., Melsungen, Germany) was performed at mid-thigh level with a high-frequency linear ultrasound transducer. All regional anesthesia was performed by a trained anesthesiologist. Ultrasound pictures (pre-injection and post-injection) was obtained to verify proper local anesthetic placement.
Peri-articular injection included combination of Exparel 266 mg (20 ml vial) with 20 ml of 0.5% bupivacaine, and normal saline to a total volume of 120 ml. The injection was meticulously administered prior and after cementation in the posterior capsule, posteromedial structures, the periarticular synovium, extensor apparatus, pes anserinus, anteromedial capsule, periosteum, iliotibial band, and subcutaneous plane. Injections were performed using 20-mL syringes with 22-gauge needle, minimal leakage. Visible tissue expansion was achieved.